The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -35.50%.However, over the last six months, we can see a stronger performance of -38.42%. Over the last 30 days, the price of DNA has leaped by -17.42%. And in the last five days, it has fallen by 0.00%.
Ginkgo Bioworks Holdings Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $2.55 on 07/19/23 and the lowest value was $1.03 on 03/18/24.
52-week price history of DNA Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Ginkgo Bioworks Holdings Inc’s current trading price is -57.17% away from its 52-week high, while its distance from the 52-week low is 5.83%. The stock’s price range during this period has varied between$1.03 and $2.55. The Ginkgo Bioworks Holdings Inc’s shares, which operate in the Healthcare, saw a trading volume of around 11.27 million for the day, a figure considerably lower than their average daily volume of 22.61 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Ginkgo Bioworks Holdings Inc (DNA) has experienced a quarterly decline of -38.07% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.22B and boasts a workforce of 1218 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.3825, with a change in price of -0.2400. Similarly, Ginkgo Bioworks Holdings Inc recorded 21,967,604 in trading volume during the last 100 days, posting a change of -18.05%.
DNA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for DNA stands at 0.22. Similarly, the long-term debt-to-equity ratio is also 0.20.
DNA Stock Stochastic Average
Ginkgo Bioworks Holdings Inc’s raw stochastic average for the past 50 days is presently 10.34%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 10.34%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 12.07% and 14.75%, respectively.
